Aptuit buys Evotec's development business
USA-based Aptuit, which is focused on supporting the early drug development process, has completed its acquisition of the chemical and pharmaceutical development business of German drugmaker Evotec AG. The purchase, financial terms of which were not disclosed, includes both an active pharmaceutical ingredient facility at Oxford in the UK and a fill/finish site in Glasgow, Scotland.
Completes global API network
Aptuit said that the new facilities complete its global API chain, which currently includes small-scale units in the USA as well as a recently-established state-of-the-art production center in Hyderabad, India (Marketletter June 25) At present, the Connecticut-headquartered firm provides its services to a client base of more than 750 pharmaceutical innovators and drug development companies around the world.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze